Ascension Seton Medical Center
- Type
- Teaching hospital
- Where
- Austin, TX
- Medicare CCN
- 450056
- Received
- $1,205,705 in 328 records, 2022 ($72,079 general, $1,133,626 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: ASCENSION SETON MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 74 | $72,079 |
| 2022 | Research payment | 254 | $1,133,626 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | 12 | $603,275 | 2022 |
| Medtronic, Inc. | 41 | $156,877 | 2022 |
| VERTEX PHARMACEUTICALS INCORPORATED | 3 | $85,103 | 2022 |
| Boston Scientific Corporation | 41 | $73,059 | 2022 |
| Abbott Laboratories | 53 | $67,176 | 2022 |
| Regeneron Pharmaceuticals, Inc. | 24 | $55,129 | 2022 |
| Travere Therapeutics, Inc. | 32 | $48,572 | 2022 |
| AngioDynamics, Inc. | 2 | $43,000 | 2022 |
| UCB SA | 1 | $22,750 | 2022 |
| Esperion Therapeutics, Inc. | 38 | $13,316 | 2022 |
| Merit Medical Systems Inc | 1 | $9,025 | 2022 |
| Terumo Medical Corporation | 5 | $6,152 | 2022 |
| Veryan Medical Incorporated | 3 | $3,818 | 2022 |
| Janssen Research & Development, LLC | 3 | $3,650 | 2022 |
| BTG International Inc. | 1 | $3,500 | 2022 |
| Merge Healthcare Incorporated | 60 | $3,147 | 2022 |
| KLS-Martin L.P. | 1 | $3,000 | 2022 |
| HEARTFLOW, INC. | 1 | $2,350 | 2022 |
| Genentech USA, Inc. | 1 | $1,200 | 2022 |
| Mallinckrodt Hospital Products Inc. | 1 | $875 | 2022 |
| Stryker Corporation | 1 | $430 | 2022 |
| Cochlear Americas | 1 | $178 | 2022 |
| Hikma Pharmaceuticals USA | 1 | $88 | 2022 |
| Linvatec Corporation | 1 | $29 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 254 | $1,133,626 |
| Long term medical supply or device loan | 3 | $43,029 |
| Debt forgiveness | 3 | $9,633 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $5,600 |
| Space rental or facility fees (teaching hospital only) | 2 | $4,200 |
| Education | 1 | $3,500 |
| Food and Beverage | 61 | $3,236 |
| Consulting Fee | 3 | $2,880 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Medtronic, Inc. | $58,586 | Research payment | In-kind items and services | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-12-31 | AngioDynamics, Inc. | $30,000 | Long term medical supply or device loan | In-kind items and services | Auryon Laser System 100-120 Vac Device, ET | 2022 | |
| 2022-12-31 | AngioDynamics, Inc. | $13,000 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2022 | |
| 2022-12-31 | Stryker Corporation | $430 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | Linvatec Corporation | $29 | Long term medical supply or device loan | In-kind items and services | BEAMER ACCESSORIES Device, GENERAL SURGERY | 2022 | |
| 2022-12-21 | Medtronic, Inc. | $10,681 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2022 |
| 2022-12-08 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | CONFIRM RX Device, Cardiac Rhythm Management | Confirm Rx Insertable Cardiac Monitor SMART Registry | 2022 |
| 2022-11-30 | Medtronic, Inc. | $160 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-11-28 | Travere Therapeutics, Inc. | $300 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-11-22 | Merit Medical Systems Inc | $9,025 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-11-22 | Regeneron Pharmaceuticals, Inc. | $316 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-11-21 | Boston Scientific Corporation | $2,620 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-11-21 | Boston Scientific Corporation | $940 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-11-21 | Boston Scientific Corporation | $940 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-11-17 | JAZZ PHARMACEUTICALS INC. | $55,500 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T | 2022 |
| 2022-11-17 | Medtronic, Inc. | $1,443 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-11-17 | Medtronic, Inc. | $1,310 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-11-17 | Genentech USA, Inc. | $1,200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | 2022 | |
| 2022-11-17 | Medtronic, Inc. | $923 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-11-15 | Regeneron Pharmaceuticals, Inc. | $633 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-11-09 | Abbott Laboratories | $2,094 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-11-09 | Abbott Laboratories | $524 | Research payment | Cash or cash equivalent | CONFIRM RX Device, Cardiac Rhythm Management | Confirm Rx Insertable Cardiac Monitor SMART Registry | 2022 |
| 2022-11-08 | Medtronic, Inc. | $134 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-11-08 | Medtronic, Inc. | $134 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-11-08 | Medtronic, Inc. | $134 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-11-07 | Boston Scientific Corporation | $9,448 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-11-07 | Boston Scientific Corporation | $51 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-11-07 | Boston Scientific Corporation | $51 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-11-02 | Regeneron Pharmaceuticals, Inc. | $1,161 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-11-01 | Medtronic, Inc. | $3,291 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2022 |
| 2022-11-01 | Merge Healthcare Incorporated | $87 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-10-27 | Medtronic, Inc. | $1,443 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-10-26 | Regeneron Pharmaceuticals, Inc. | $1,055 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-10-25 | UCB SA | $22,750 | Research payment | Cash or cash equivalent | Vimpat Drug, Neurology | A MULTICENTER, OPEN-LABEL, RANDOMIZED, ACTIVE COMPARATOR STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF | 2022 |
| 2022-10-19 | Boston Scientific Corporation | $1,159 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-10-10 | Merge Healthcare Incorporated | $19 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-10-09 | Merge Healthcare Incorporated | $53 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-10-07 | Regeneron Pharmaceuticals, Inc. | $633 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-10-03 | Boston Scientific Corporation | $5,492 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-10-03 | Medtronic, Inc. | $320 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-09-29 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | SJM MASTERS SERIES Device, Vascular | A Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as | 2022 |
| 2022-09-29 | Medtronic, Inc. | $1,443 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-09-29 | Medtronic, Inc. | $948 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-09-29 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-09-29 | Abbott Laboratories | $700 | Research payment | Cash or cash equivalent | SJM MASTERS SERIES Device, Vascular | A Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as | 2022 |
| 2022-09-29 | Abbott Laboratories | $93 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-09-29 | Abbott Laboratories | $93 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-09-29 | Abbott Laboratories | $62 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-09-29 | Abbott Laboratories | $62 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-09-29 | Abbott Laboratories | $62 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-09-29 | Abbott Laboratories | $62 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-09-29 | Abbott Laboratories | $31 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-09-28 | Regeneron Pharmaceuticals, Inc. | $3,514 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-09-22 | Medtronic, Inc. | $1,500 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2022 |
| 2022-09-20 | Regeneron Pharmaceuticals, Inc. | $4,793 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-09-20 | Boston Scientific Corporation | $2,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-09-20 | Boston Scientific Corporation | $1,807 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-09-20 | Boston Scientific Corporation | $51 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-09-20 | Boston Scientific Corporation | $51 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-09-20 | Boston Scientific Corporation | $51 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-09-20 | Boston Scientific Corporation | $51 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $3,810 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $3,352 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $3,242 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $3,179 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $3,007 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $3,007 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $2,759 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $2,732 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $2,692 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $1,317 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $1,317 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $1,317 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $1,317 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $1,251 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $1,250 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $1,224 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $1,168 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $1,141 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $1,141 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $300 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-15 | Travere Therapeutics, Inc. | $279 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-09-13 | JAZZ PHARMACEUTICALS INC. | $92,500 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T | 2022 |
| 2022-09-09 | Regeneron Pharmaceuticals, Inc. | $5,079 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-09-09 | Terumo Medical Corporation | $500 | Research payment | Cash or cash equivalent | PROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR | 2022 | |
| 2022-09-08 | Medtronic, Inc. | $1,738 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2022 |
| 2022-09-08 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure | Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II) | 2022 |
| 2022-09-06 | Boston Scientific Corporation | $8,442 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-09-06 | Medtronic, Inc. | $922 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-09-01 | JAZZ PHARMACEUTICALS INC. | $2,500 | Research payment | Cash or cash equivalent | RYLAZE Drug, HEMATOLOGY/ONCOLOGY | AN OPEN-LABEL MULTICENTER STUDY OF RECOMBINANT CRISANTASPASE PRODUCED IN PSEUDOMONAS FLUORESCENS (RC-P) IN PATIENTS WITH | 2022 |
| 2022-09-01 | JAZZ PHARMACEUTICALS INC. | $2,500 | Research payment | Cash or cash equivalent | RYLAZE Drug, HEMATOLOGY/ONCOLOGY | AN OPEN-LABEL MULTICENTER STUDY OF RECOMBINANT CRISANTASPASE PRODUCED IN PSEUDOMONAS FLUORESCENS (RC-P) IN PATIENTS WITH | 2022 |
| 2022-09-01 | JAZZ PHARMACEUTICALS INC. | $2,000 | Research payment | Cash or cash equivalent | RYLAZE Drug, HEMATOLOGY/ONCOLOGY | AN OPEN-LABEL MULTICENTER STUDY OF RECOMBINANT CRISANTASPASE PRODUCED IN PSEUDOMONAS FLUORESCENS (RC-P) IN PATIENTS WITH | 2022 |
| 2022-08-24 | Abbott Laboratories | $5,129 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-08-17 | Regeneron Pharmaceuticals, Inc. | $800 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-08-16 | Boston Scientific Corporation | $940 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-08-16 | Boston Scientific Corporation | $179 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-08-16 | Merge Healthcare Incorporated | $67 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-08-16 | Merge Healthcare Incorporated | $67 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-08-16 | Merge Healthcare Incorporated | $67 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-08-16 | Boston Scientific Corporation | $51 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-08-16 | Merge Healthcare Incorporated | $17 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-08-16 | Merge Healthcare Incorporated | $17 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-08-16 | Merge Healthcare Incorporated | $11 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-08-16 | Merge Healthcare Incorporated | $11 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-08-16 | Merge Healthcare Incorporated | $11 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-08-12 | Terumo Medical Corporation | $1,920 | Research payment | Cash or cash equivalent | PROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR | 2022 | |
| 2022-08-12 | Terumo Medical Corporation | $1,076 | Research payment | Cash or cash equivalent | PROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR | 2022 | |
| 2022-08-11 | Medtronic, Inc. | $2,980 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2022 |
| 2022-08-11 | Medtronic, Inc. | $1,500 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-08-09 | Regeneron Pharmaceuticals, Inc. | $211 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-08-04 | Medtronic, Inc. | $922 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-08-03 | Medtronic, Inc. | $4,230 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2022 |
| 2022-08-03 | Abbott Laboratories | $1,587 | Research payment | Cash or cash equivalent | CONFIRM RX Device, Cardiac Rhythm Management | Confirm Rx Insertable Cardiac Monitor SMART Registry | 2022 |
| 2022-08-02 | Esperion Therapeutics, Inc. | $50 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-01 | Boston Scientific Corporation | $814 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-07-27 | Medtronic, Inc. | $1,500 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2022 |
| 2022-07-27 | Medtronic, Inc. | $240 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2022 |
| 2022-07-22 | Terumo Medical Corporation | $1,696 | Research payment | Cash or cash equivalent | PROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR | 2022 | |
| 2022-07-21 | Regeneron Pharmaceuticals, Inc. | $1,583 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-07-21 | Abbott Laboratories | $1,250 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | $1,352 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-18 | Boston Scientific Corporation | $2,097 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-07-17 | Medtronic, Inc. | $6,500 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2022 |
| 2022-07-17 | Medtronic, Inc. | $1,250 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2022 |
| 2022-07-17 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2022 |
| 2022-07-15 | Medtronic, Inc. | $960 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2022 |
| 2022-07-14 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-07-13 | Abbott Laboratories | $1,574 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2022 |
| 2022-07-08 | Medtronic, Inc. | $2,980 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2022 |
| 2022-07-08 | Regeneron Pharmaceuticals, Inc. | $1,583 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-07-07 | Travere Therapeutics, Inc. | $400 | Research payment | Cash or cash equivalent | Chenodal Drug, Hepatology | A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | 2022 |
| 2022-07-05 | Boston Scientific Corporation | $14,500 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-07-05 | Boston Scientific Corporation | $4,098 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-07-05 | Veryan Medical Incorporated | $1,428 | Research payment | Cash or cash equivalent | BioMimics 3D Vascular Stent System Device, Vascular Stent | A prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of p | 2022 |
| 2022-07-05 | Veryan Medical Incorporated | $1,200 | Research payment | Cash or cash equivalent | BioMimics 3D Vascular Stent System Device, Vascular Stent | A prospective, multicentre observational study to evaluate the BioMimics 3D1 Vascular Stent System in the treatment of p | 2022 |
| 2022-07-01 | Esperion Therapeutics, Inc. | $4 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-01 | Esperion Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-30 | Regeneron Pharmaceuticals, Inc. | $1,173 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-06-29 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | INFUSE BONE GRAFT Device, Bone Matrix/Graft | TLIF IDE Pivotal Study | 2022 |
| 2022-06-24 | Esperion Therapeutics, Inc. | $1 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-23 | Regeneron Pharmaceuticals, Inc. | $5,625 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-06-23 | Abbott Laboratories | $63 | Research payment | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure | Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II) | 2022 |
| 2022-06-22 | Medtronic, Inc. | $2,049 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2022 |
| 2022-06-22 | Merge Healthcare Incorporated | $150 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-06-22 | Merge Healthcare Incorporated | $150 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-06-22 | Merge Healthcare Incorporated | $150 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-06-22 | Merge Healthcare Incorporated | $23 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-06-22 | Merge Healthcare Incorporated | $3 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-06-21 | Esperion Therapeutics, Inc. | $1,352 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-21 | Esperion Therapeutics, Inc. | $1,352 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-21 | Esperion Therapeutics, Inc. | $1,352 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-21 | Esperion Therapeutics, Inc. | $1,352 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-21 | Esperion Therapeutics, Inc. | $1,352 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-21 | Boston Scientific Corporation | $828 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-06-21 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-21 | Esperion Therapeutics, Inc. | $32 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-21 | Esperion Therapeutics, Inc. | $32 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-21 | Merge Healthcare Incorporated | $16 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-06-16 | JAZZ PHARMACEUTICALS INC. | $135,375 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T | 2022 |
| 2022-06-16 | Abbott Laboratories | $124 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-06-08 | BTG International Inc. | $3,500 | Education | Cash or cash equivalent | CYANOKIT Drug, treatment of acute cyanide intoxication | 2022 | |
| 2022-06-07 | Boston Scientific Corporation | $814 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-06-06 | Medtronic, Inc. | $2,400 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-06-02 | Hikma Pharmaceuticals USA | $88 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-05-27 | Cochlear Americas | $178 | Debt forgiveness | Cash or cash equivalent | Cochlear Device, Implantable hearing solution | 2022 | |
| 2022-05-25 | Abbott Laboratories | $4,450 | Research payment | Cash or cash equivalent | CONFIRM RX Device, Cardiac Rhythm Management | Confirm Rx Insertable Cardiac Monitor SMART Registry | 2022 |
| 2022-05-25 | Abbott Laboratories | $1,471 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2022 |
| 2022-05-25 | Medtronic, Inc. | $250 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | $194 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | $32 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-20 | Merge Healthcare Incorporated | $23 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-05-19 | Regeneron Pharmaceuticals, Inc. | $527 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-05-12 | Medtronic, Inc. | $1,443 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-05-12 | Medtronic, Inc. | $1,443 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-05-12 | Regeneron Pharmaceuticals, Inc. | $705 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2022 |
| 2022-05-12 | Medtronic, Inc. | $601 | Research payment | Cash or cash equivalent | FLOWMET-R Device, Intraprocedural Monitoring | FlowMet-R for PAD and CLI | 2022 |
| 2022-05-10 | Medtronic, Inc. | $2,484 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | Define AFib | 2022 |
| 2022-05-04 | Abbott Laboratories | $3,690 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-05-04 | Abbott Laboratories | $1,883 | Research payment | Cash or cash equivalent | SJM MASTERS SERIES Device, Vascular | A Single Arm, Non-randomized, Multi-center Clinical Study of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve as | 2022 |
| 2022-05-02 | Medtronic, Inc. | $3,680 | Research payment | Cash or cash equivalent | CARDIOBLATE Device, Ablation | Terminate AF | 2022 |
| 2022-05-02 | Boston Scientific Corporation | $1,366 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-05-02 | Boston Scientific Corporation | $565 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-04-28 | Merge Healthcare Incorporated | $63 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-28 | Merge Healthcare Incorporated | $63 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-28 | Merge Healthcare Incorporated | $63 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-28 | Merge Healthcare Incorporated | $63 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-28 | Merge Healthcare Incorporated | $63 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-28 | Merge Healthcare Incorporated | $63 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-28 | Merge Healthcare Incorporated | $63 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-28 | Merge Healthcare Incorporated | $63 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-28 | Merge Healthcare Incorporated | $63 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-28 | Merge Healthcare Incorporated | $63 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 |
The latest 200 records of 328.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Austin, TX, county Travis County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Austin, TX | County Travis County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 979,539 | 1,330,015 | 30,188,424 |
| Population, 2020 census P1 | 961,855 | 1,290,188 | 29,145,505 |
| Median age B01002 | 34.7 | 35.6 | 35.6 |
| Under 18 B01001 | 18.0% | 20.2% | 25.0% |
| 65 and over B01001 | 10.4% | 11.0% | 13.4% |
| Households B11001 | 456,113 | 583,747 | 10,992,816 |
| Foreign born B05002 | 18.7% | 18.1% | 17.6% |
| Median household income B19013 | $93,658 | $99,611 | $78,476 |
| Median family income B19113 | $128,808 | $131,256 | $94,599 |
| Per capita income B19301 | $62,862 | $62,607 | $40,752 |
| Poverty rate B17001 | 12.0% | 10.9% | 13.8% |
| Unemployment rate B23025 | 4.7% | 4.6% | 5.3% |
| Civilian labor force B23025 | 617,774 | 799,524 | 15,233,563 |
| Mean commute (minutes) B08013 | 23.7 | 25.2 | 26.7 |
| Bachelor's degree or higher B15003 | 59.6% | 56.6% | 33.8% |
| Housing units B25001 | 483,071 | 618,236 | 12,128,515 |
| Owner-occupied B25003 | 43.4% | 52.1% | 62.6% |
| Renters B25003 | 56.6% | 47.9% | 37.4% |
| Median home value B25077 | $555,300 | $523,000 | $283,800 |
| Median gross rent B25064 | $1,729 | $1,744 | $1,403 |
| White, not Hispanic B03002 | 47.0% | 46.9% | 39.1% |
| Black B03002 | 7.3% | 7.8% | 11.9% |
| Hispanic or Latino B03002 | 31.9% | 32.6% | 39.7% |
| Asian B03002 | 9.0% | 7.8% | 5.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Austin, TX.
Comments